Castleman's disease pathophysiology

Castleman's disease Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Castleman's disease from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Castleman's disease pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Castleman's disease pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Castleman's disease pathophysiology
CDC on Castleman's disease pathophysiology
Castleman's disease pathophysiology in the news
Blogs on Castleman's disease pathophysiology
Directions to Hospitals Treating Castleman's disease
Risk calculators and risk factors for Castleman's disease pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Pathophysiology

In all cases, Castleman's disease is likely due to hypersecretion of the cytokine IL-6. In KSHV positive tumors, this is most likely due to expression of the a virus-encoded cytokine, vIL-6, while KSHV negative tumors appear to be the result of over secretion of human IL-6.